NGIOTENSlN converting enzyme (ACE)(EC 3.4. 15. 1) converts angiotensin I to the potent
hypertensive octapeptide angiotensin II by releasing the C-terminal dipeptide. l This enzyme …

1. Captopril or SQ 14 225, administered orally twice a day, reduced the blood pressure of
hypertensive patients whatever their clinical diagnosis and even when their plasma renin …

The purpose of this study was to assess the effect of a daily low dose of the angiotensin‐
converting enzyme (ACE) inhibitors, captopril or enalapril, in mild essential hypertension …

Three orally active angiotensin-converting enzyme inhibitors, captopril, MK 421 and RHC
3659, were compared in normal volunteers by evaluating their blocking effect on blood …

Captopril, an orally active inhibitor of angiotensin converting enzyme, was administered for
12 months to 20 patients with mild or moderate essential hypertension who initially …

The blood pressure (BP), heart rate (HR), and humoral effects of single intravenous (iv)
doses of the angiotensin-converting enzyme (ACE) inhibitor captopril was investigated in …

Captopril (SQ 14225) or hydrochlorothiazide was given to a group of 20 patients with
essential hypertension for four weeks, followed by eight weeks' therapy with both drugs …

Captopril Research Group of Japan made an evaluation of clinical usefulness of captopril in
the treatment of mild to moderate essential hypertension. A relatively low frequency of side …

The effect of the converting enzyme inhibitor captopril as long term treatment was
investigated in 14 patients with severe congestive heart failure in a double blind trial …

Synopsis: Captopril 1 is the first orally active inhibitor of angiotensin-converting enzyme to
become available. It has been studied to date primarily in hypertension. In mild to moderate …